<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00805285</url>
  </required_header>
  <id_info>
    <org_study_id>H-30365</org_study_id>
    <nct_id>NCT00805285</nct_id>
  </id_info>
  <brief_title>The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis</brief_title>
  <official_title>Oral Budesonide and Rectal Hydrocortisone for the Treatment of Extensive Ulcerative Colitis: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if the combination of oral budesonide and rectal
      hydrocortisone improves symptoms in patients with active ulcerative colitis. Also, we would
      like to determine if oral budesonide and rectal hydrocortisone has fewer and less severe side
      effects compared to standard steroids (prednisone).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ulcerative colitis (UC) is a common chronic inflammatory condition of the intestines that
      results in bloody diarrhea, abdominal pain, and extraintestinal manifestations of disease.
      The disease course is typically chronic, characterized by periodic exacerbations followed by
      symptom- free intervals; less commonly symptoms are continuous and unrelenting. The symptoms
      and disease course have a profound, detrimental impact on the quality of life in patients
      with UC.

      The initial therapeutic approach depends upon both the extent of colonic involvement and the
      severity of the disease process at presentation. Typically, patients are treated based on a
      pyramid or &quot;Step up&quot; approach. If patients have mild symptoms, they receive less powerful
      therapies lower in the pyramid with fewer side effects. Patients with disease confined to
      distal colon are typically treated with topical therapies including either 5-ASA or steroid
      enemas. However, as symptoms worsen or if severe at the time of diagnosis, patients receive
      more aggressive therapies higher in the pyramid including steroids. Despite medical therapy,
      50% will have colectomy or become steroid dependent one year after receiving steroids.

      Steroids are associated with significant side effects. Adverse consequences of steroids are
      related to dose and duration of exposure, and include but are not limited to cosmetic side
      effects, ocular disease (glaucoma, cataracts), diabetes, hypertension, vascular disease,
      osteoporosis, neuropsychiatric complications, and increased risk of infection.

      Newer &quot;designer&quot; corticosteroids including budesonide have reduced systemic bioavailability
      and high local anti-inflammatory activity; as a result it is associated with fewer and less
      severe side effects. Studies have proven the efficacy of budesonide in inducing remission in
      active Crohn's disease. However, the data for the use of oral budesonide in patients with UC
      is less extensive. However, the data regarding the efficacy of topical therapy for left-sided
      UC is extensive. Randomized controlled trials of budesonide enemas have demonstrated similar
      efficacy and safety profile to hydrocortisone enemas in the induction of remission of left
      sided UC. We have chosen to utilize hydrocortisone enemas in our study as it is widely
      available in the United States.

      A 52-week open-label pilot study will be performed at the University of Maryland Medical
      Center. Subjects will include patients with previously or newly diagnosed extensive
      ulcerative colitis. Patients will be treated with oral budesonide and rectal hydrocortisone
      for 8 weeks followed by a predetermined taper. All patients will undergo research clinic
      visits at enrollment and week 8. During these visits, patients will complete a series of
      questionnaires that measure the patient's disease activity, quality of life, side effects,
      medical compliance, and other parameters. Blood draws and stool studies are required at each
      study visit to monitor blood counts, electrolytes, liver function, inflammatory markers, and
      adrenal function. Additionally, at week 16, an ACTH (cosyntropin) stimulation test will be
      performed. After obtaining a basal cortisol level, 250 ug of cosyntropin is given
      intravenously. Plasma samples of cortisol will then be drawn at 30 minutes to assess for
      adrenal insufficiency. Close follow-up with eight 30-min telephone sessions (every 2-3 weeks)
      will also be conducted to assess disease activity and adverse events.

      The goal of this study is to determine whether combination therapy using oral budesonide and
      topical hydrocortisone will result in the induction of remission in patients with active
      extensive ulcerative colitis. Further, we aim to show that combination therapy is better
      tolerated and has less severe side effects compared to conventional therapy with prednisone.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to insufficient enrollment
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Simple Clinical Colitis Disease Activity (SCCAI)</measure>
    <time_frame>0, 2, 4, 6, and 8 weeks</time_frame>
    <description>Scores range from 0-19. Higher scores indicated increased disease severity. A score less than 3 is consistent with clinical remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short Inflammatory Bowel Disease Questionnaire (SIBDQ)</measure>
    <time_frame>Week 0 and 8</time_frame>
    <description>Scores range from 10-70 where higher scores indicated better quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACTH Stimulation Test</measure>
    <time_frame>Week 16</time_frame>
    <description>An increase in cortisol after stimulation by ACTH is normal. Blood cortisol after ACTH stimulation should be greater than 18 - 20 mcg/dL, depending on the dose of cosyntropin used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>0, 2, 4, 6, 8, 11, 14, 20, 26, and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C Reactive Protein</measure>
    <time_frame>Week 0 and 8</time_frame>
    <description>Higher values indicated increased disease activity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Combination Oral Budesonide and Rectal Hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination Oral Budesonide and Rectal Hydrocortisone</intervention_name>
    <description>Budesonide 9 mg PO (oral) daily and hydrocortisone 100 mL PR (enema) for an 8-week period. The doses of each drug to be used in the pilot study are standard doses used in clinical practice. After 8-weeks, the budesonide will be tapered in the following manner: 1) budesonide 6 mg PO daily and hydrocortisone 100 ml PR every other day (EOD) for 3 weeks then 2) budesonide 3 mg PO daily and hydrocortisone 100 ml PR 2 x per week for 3 weeks then 3) discontinue budesonide.</description>
    <arm_group_label>Combination Oral Budesonide and Rectal Hydrocortisone</arm_group_label>
    <other_name>Entocort</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written, voluntary, informed consent given

          -  18 years or older

          -  Speak and read English

          -  Extensive ulcerative colitis based upon endoscopy, histopathology, and clinical
             symptoms

          -  SCCAI Score &gt; 3

          -  Presence of diarrhea (3 or more bowel movements per 24 hours) AND grossly visible
             blood in stool

        Exclusion Criteria:

          -  Serum creatinine &gt; 2.0 mg/dL

          -  Pregnant or breastfeeding

          -  Prior history of total or subtotal colectomy, or currently has an ostomy

          -  History or suspicion of Crohn's disease or Indeterminate colitis

          -  Diagnosis of any condition deemed by the investigator inhibiting completion of the
             trial

          -  Initiated therapy with or change in mesalamine dose within the last 4 weeks

          -  Change in azathioprine, 6-mercaptopurine, or cyclosporine within the last 8 weeks

          -  Currently taking or have used corticosteroids within the last 8 weeks

          -  Rectally administered mesalamine or steroids within the last 2 weeks

          -  Current or prior use of anti-TNF alpha agents within the last 8 weeks

          -  Experimental ulcerative colitis agents within the last 8 weeks

          -  Concomitant use of CYP3A4 activity inhibitor (e.g. ketoconazole, itraconazole,
             ritonavir, indinavir, erythromycin)

          -  Uncontrolled diabetes (HgA1c &gt; 8.0) within 1 year

          -  Unstable Coronary artery disease/Class III/IV CHF

          -  Decompensated cirrhosis (e.g. encephalopathy, renal failure, ascites, GIB)

          -  Any known infection requiring antibiotics

          -  Active Clostridium difficile infection

          -  COPD requiring home oxygen

          -  HIV/AIDS with CD4 &lt; 200 or AIDs-defining illnesses/infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond K Cross, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leyla J Ghazi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.umm.edu/ibd/research.htm</url>
    <description>University of Maryland IBD Program</description>
  </link>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2008</study_first_submitted>
  <study_first_submitted_qc>December 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2008</study_first_posted>
  <results_first_submitted>January 24, 2013</results_first_submitted>
  <results_first_submitted_qc>March 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 13, 2013</results_first_posted>
  <last_update_submitted>March 30, 2013</last_update_submitted>
  <last_update_submitted_qc>March 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>Budesonide</keyword>
  <keyword>Corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Combination Oral Budesonide and Rectal Hydrocortisone</title>
          <description>Budesonide 9 mg po daily and Rectal Hydrocortisone once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The only enrolled patient was withdrawn secondary to disease worsening.</population>
      <group_list>
        <group group_id="B1">
          <title>Combination Oral Budesonide and Rectal Hydrocortisone</title>
          <description>Intervention Arm</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Simple Clinical Colitis Disease Activity (SCCAI)</title>
        <description>Scores range from 0-19. Higher scores indicated increased disease severity. A score less than 3 is consistent with clinical remission.</description>
        <time_frame>0, 2, 4, 6, and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Oral Budesonide and Rectal Hydrocortisone</title>
            <description>Intervention Arm</description>
          </group>
        </group_list>
        <measure>
          <title>Simple Clinical Colitis Disease Activity (SCCAI)</title>
          <description>Scores range from 0-19. Higher scores indicated increased disease severity. A score less than 3 is consistent with clinical remission.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Short Inflammatory Bowel Disease Questionnaire (SIBDQ)</title>
        <description>Scores range from 10-70 where higher scores indicated better quality of life.</description>
        <time_frame>Week 0 and 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Oral Budesonide and Rectal Hydrocortisone</title>
            <description>Intervention Arm</description>
          </group>
        </group_list>
        <measure>
          <title>Short Inflammatory Bowel Disease Questionnaire (SIBDQ)</title>
          <description>Scores range from 10-70 where higher scores indicated better quality of life.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACTH Stimulation Test</title>
        <description>An increase in cortisol after stimulation by ACTH is normal. Blood cortisol after ACTH stimulation should be greater than 18 - 20 mcg/dL, depending on the dose of cosyntropin used.</description>
        <time_frame>Week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Oral Budesonide and Rectal Hydrocortisone</title>
            <description>Intervention Arm</description>
          </group>
        </group_list>
        <measure>
          <title>ACTH Stimulation Test</title>
          <description>An increase in cortisol after stimulation by ACTH is normal. Blood cortisol after ACTH stimulation should be greater than 18 - 20 mcg/dL, depending on the dose of cosyntropin used.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <time_frame>0, 2, 4, 6, 8, 11, 14, 20, 26, and 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Oral Budesonide and Rectal Hydrocortisone</title>
            <description>Intervention Arm</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <units>Adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C Reactive Protein</title>
        <description>Higher values indicated increased disease activity</description>
        <time_frame>Week 0 and 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Oral Budesonide and Rectal Hydrocortisone</title>
            <description>Intervention Arm</description>
          </group>
        </group_list>
        <measure>
          <title>C Reactive Protein</title>
          <description>Higher values indicated increased disease activity</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Combination Oral Budesonide and Rectal Hydrocortisone</title>
          <description>Intervention Arm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of ulcerative colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Portal vein and superior mesenteric vein thrombosis</sub_title>
                <description>The only enrolled patient was found to have a portal and superior mesenteric vein thrombosis. This was thought to be related to the underlying ulcerative colitis and not related to the intervention.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated early by the University of Maryland HRPO secondary to limited recruitment of participants. This resulted in an inability to analyze the results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Raymond Cross, MD, MS</name_or_title>
      <organization>University of Maryland, Baltimore</organization>
      <phone>410-706-3387</phone>
      <email>rcross@medicine.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

